Assembly Biosciences (NASDAQ:ASMB) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Assembly Biosciences (NASDAQ:ASMB) in a research note released on Thursday,Benzinga reports. They currently have a $50.00 target price on the biopharmaceutical company’s stock.

A number of other research firms have also recently issued reports on ASMB. Wall Street Zen raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a research note on Saturday, March 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $41.75.

Assembly Biosciences Trading Up 0.7%

Shares of ASMB stock opened at $28.87 on Thursday. The company has a market capitalization of $457.88 million, a P/E ratio of -39.01 and a beta of 1.11. The business’s 50 day moving average is $27.96 and its two-hundred day moving average is $29.71. Assembly Biosciences has a 12-month low of $7.75 and a 12-month high of $39.71.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings data on Thursday, March 19th. The biopharmaceutical company reported $2.48 EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $2.99. The business had revenue of $42.47 million during the quarter, compared to analysts’ expectations of $7.42 million. Assembly Biosciences had a negative return on equity of 5.63% and a negative net margin of 8.47%. On average, research analysts predict that Assembly Biosciences will post -6.87 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Assembly Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ASMB. Bank of America Corp DE increased its position in shares of Assembly Biosciences by 6,382.7% during the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 3,319 shares during the last quarter. Seven Fleet Capital Management LP purchased a new stake in Assembly Biosciences in the 4th quarter valued at about $147,000. Acadian Asset Management LLC lifted its position in Assembly Biosciences by 42.1% in the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock valued at $219,000 after buying an additional 6,823 shares during the last quarter. Charles Schwab Investment Management Inc. purchased a new position in Assembly Biosciences during the fourth quarter worth about $228,000. Finally, Virtus Investment Advisers LLC purchased a new position in Assembly Biosciences during the fourth quarter worth about $251,000. Institutional investors and hedge funds own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.